AAPL333.74+0.48 (+0.14%) ▲|ABBV254.59+0.20 (+0.08%) ▲|ABT100.67+1.84 (+1.86%) ▲|ACN143.46-1.15 (-0.80%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.04+1.12 (+0.66%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.26-6.31 (-1.75%) ▼|BA214.76+0.42 (+0.19%) ▲|BAC61.25-0.24 (-0.39%) ▼|BKNG181.65-2.96 (-1.60%) ▼|BLK1,074.11-12.94 (-1.19%) ▼|BMY60.70+0.19 (+0.31%) ▲|BNY157.22-3.64 (-2.26%) ▼|BRK-B491.19-1.93 (-0.39%) ▼|C129.90-1.81 (-1.37%) ▼|CAT885.83+8.66 (+0.99%) ▲|CL92.87-1.20 (-1.28%) ▼|CMCSA23.81-0.30 (-1.22%) ▼|COF208.72-3.21 (-1.51%) ▼|COP114.12+1.28 (+1.13%) ▲|COST938.21-7.37 (-0.78%) ▼|CRM171.83-0.85 (-0.49%) ▼|CSCO112.82+3.16 (+2.88%) ▲|CVS106.95+0.45 (+0.42%) ▲|CVX186.71+2.85 (+1.55%) ▲|DE597.34-1.64 (-0.27%) ▼|DHR203.62-1.39 (-0.68%) ▼|DIS97.35-2.37 (-2.37%) ▼|DUK124.85-1.26 (-1.00%) ▼|EMR139.80+0.72 (+0.52%) ▲|FDX313.83-4.37 (-1.37%) ▼|GD368.09-0.73 (-0.20%) ▼|GE349.93+4.20 (+1.21%) ▲|GEV1,059.27+23.05 (+2.22%) ▲|GILD134.97-1.33 (-0.98%) ▼|GM76.61-1.11 (-1.43%) ▼|GOOG342.44-11.37 (-3.21%) ▼|GOOGL342.96-11.51 (-3.25%) ▼|GS1,074.05-21.41 (-1.95%) ▼|HD340.21-7.81 (-2.24%) ▼|HON225.41-0.92 (-0.41%) ▼|IBM212.15-6.90 (-3.15%) ▼|INTC96.04-0.94 (-0.97%) ▼|INTU293.29-1.50 (-0.51%) ▼|ISRG349.60-52.73 (-13.11%) ▼|JNJ253.00+3.03 (+1.21%) ▲|JPM343.17+0.02 (+0.01%) ▲|KO81.08-3.84 (-4.52%) ▼|LIN514.69-6.06 (-1.16%) ▼|LLY1,174.55+5.38 (+0.46%) ▲|LMT511.41-2.11 (-0.41%) ▼|LOW209.98-6.18 (-2.86%) ▼|LRCX312.28-8.68 (-2.70%) ▼|MA542.57-8.97 (-1.63%) ▼|MCD267.67-5.79 (-2.12%) ▼|MDLZ60.82-0.60 (-0.98%) ▼|MDT83.03-0.53 (-0.63%) ▼|META646.96-17.58 (-2.65%) ▼|MMM160.78-1.00 (-0.62%) ▼|MO74.10+1.07 (+1.47%) ▲|MRK127.29-0.34 (-0.27%) ▼|MS215.35-3.03 (-1.39%) ▼|MSFT395.88-5.22 (-1.30%) ▼|MU876.57+23.37 (+2.74%) ▲|NEE88.71-0.64 (-0.72%) ▼|NFLX69.34-5.02 (-6.75%) ▼|NKE43.72-0.86 (-1.92%) ▼|NOW104.38+0.37 (+0.35%) ▲|NVDA203.66-3.74 (-1.80%) ▼|ORCL127.24+3.03 (+2.44%) ▲|PEP136.62-2.81 (-2.02%) ▼|PFE25.05-0.10 (-0.38%) ▼|PG149.58-1.93 (-1.27%) ▼|PLTR134.04-0.41 (-0.30%) ▼|PM191.26+1.42 (+0.75%) ▲|QCOM170.40-0.27 (-0.16%) ▼|RTX194.62+0.26 (+0.13%) ▲|SBUX105.47-2.90 (-2.68%) ▼|SCHW101.87-0.93 (-0.90%) ▼|SO95.38-0.70 (-0.72%) ▼|SPG227.69-0.80 (-0.35%) ▼|T21.78-0.20 (-0.91%) ▼|TMO533.17-10.02 (-1.84%) ▼|TMUS191.53-1.32 (-0.68%) ▼|TSLA381.86-9.21 (-2.35%) ▼|TXN283.80-7.43 (-2.55%) ▼|UBER72.75-1.29 (-1.74%) ▼|UNH434.62+11.24 (+2.65%) ▲|UNP300.56+1.14 (+0.38%) ▲|UPS117.74+0.56 (+0.48%) ▲|USB63.50-0.52 (-0.80%) ▼|V358.72-6.42 (-1.76%) ▼|VZ43.51-0.37 (-0.84%) ▼|WFC87.43-0.64 (-0.73%) ▼|WMT114.48-0.47 (-0.41%) ▼|XOM147.91+1.96 (+1.34%) ▲|AAPL333.74+0.48 (+0.14%) ▲|ABBV254.59+0.20 (+0.08%) ▲|ABT100.67+1.84 (+1.86%) ▲|ACN143.46-1.15 (-0.80%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.04+1.12 (+0.66%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.26-6.31 (-1.75%) ▼|BA214.76+0.42 (+0.19%) ▲|BAC61.25-0.24 (-0.39%) ▼|BKNG181.65-2.96 (-1.60%) ▼|BLK1,074.11-12.94 (-1.19%) ▼|BMY60.70+0.19 (+0.31%) ▲|BNY157.22-3.64 (-2.26%) ▼|BRK-B491.19-1.93 (-0.39%) ▼|C129.90-1.81 (-1.37%) ▼|CAT885.83+8.66 (+0.99%) ▲|CL92.87-1.20 (-1.28%) ▼|CMCSA23.81-0.30 (-1.22%) ▼|COF208.72-3.21 (-1.51%) ▼|COP114.12+1.28 (+1.13%) ▲|COST938.21-7.37 (-0.78%) ▼|CRM171.83-0.85 (-0.49%) ▼|CSCO112.82+3.16 (+2.88%) ▲|CVS106.95+0.45 (+0.42%) ▲|CVX186.71+2.85 (+1.55%) ▲|DE597.34-1.64 (-0.27%) ▼|DHR203.62-1.39 (-0.68%) ▼|DIS97.35-2.37 (-2.37%) ▼|DUK124.85-1.26 (-1.00%) ▼|EMR139.80+0.72 (+0.52%) ▲|FDX313.83-4.37 (-1.37%) ▼|GD368.09-0.73 (-0.20%) ▼|GE349.93+4.20 (+1.21%) ▲|GEV1,059.27+23.05 (+2.22%) ▲|GILD134.97-1.33 (-0.98%) ▼|GM76.61-1.11 (-1.43%) ▼|GOOG342.44-11.37 (-3.21%) ▼|GOOGL342.96-11.51 (-3.25%) ▼|GS1,074.05-21.41 (-1.95%) ▼|HD340.21-7.81 (-2.24%) ▼|HON225.41-0.92 (-0.41%) ▼|IBM212.15-6.90 (-3.15%) ▼|INTC96.04-0.94 (-0.97%) ▼|INTU293.29-1.50 (-0.51%) ▼|ISRG349.60-52.73 (-13.11%) ▼|JNJ253.00+3.03 (+1.21%) ▲|JPM343.17+0.02 (+0.01%) ▲|KO81.08-3.84 (-4.52%) ▼|LIN514.69-6.06 (-1.16%) ▼|LLY1,174.55+5.38 (+0.46%) ▲|LMT511.41-2.11 (-0.41%) ▼|LOW209.98-6.18 (-2.86%) ▼|LRCX312.28-8.68 (-2.70%) ▼|MA542.57-8.97 (-1.63%) ▼|MCD267.67-5.79 (-2.12%) ▼|MDLZ60.82-0.60 (-0.98%) ▼|MDT83.03-0.53 (-0.63%) ▼|META646.96-17.58 (-2.65%) ▼|MMM160.78-1.00 (-0.62%) ▼|MO74.10+1.07 (+1.47%) ▲|MRK127.29-0.34 (-0.27%) ▼|MS215.35-3.03 (-1.39%) ▼|MSFT395.88-5.22 (-1.30%) ▼|MU876.57+23.37 (+2.74%) ▲|NEE88.71-0.64 (-0.72%) ▼|NFLX69.34-5.02 (-6.75%) ▼|NKE43.72-0.86 (-1.92%) ▼|NOW104.38+0.37 (+0.35%) ▲|NVDA203.66-3.74 (-1.80%) ▼|ORCL127.24+3.03 (+2.44%) ▲|PEP136.62-2.81 (-2.02%) ▼|PFE25.05-0.10 (-0.38%) ▼|PG149.58-1.93 (-1.27%) ▼|PLTR134.04-0.41 (-0.30%) ▼|PM191.26+1.42 (+0.75%) ▲|QCOM170.40-0.27 (-0.16%) ▼|RTX194.62+0.26 (+0.13%) ▲|SBUX105.47-2.90 (-2.68%) ▼|SCHW101.87-0.93 (-0.90%) ▼|SO95.38-0.70 (-0.72%) ▼|SPG227.69-0.80 (-0.35%) ▼|T21.78-0.20 (-0.91%) ▼|TMO533.17-10.02 (-1.84%) ▼|TMUS191.53-1.32 (-0.68%) ▼|TSLA381.86-9.21 (-2.35%) ▼|TXN283.80-7.43 (-2.55%) ▼|UBER72.75-1.29 (-1.74%) ▼|UNH434.62+11.24 (+2.65%) ▲|UNP300.56+1.14 (+0.38%) ▲|UPS117.74+0.56 (+0.48%) ▲|USB63.50-0.52 (-0.80%) ▼|V358.72-6.42 (-1.76%) ▼|VZ43.51-0.37 (-0.84%) ▼|WFC87.43-0.64 (-0.73%) ▼|WMT114.48-0.47 (-0.41%) ▼|XOM147.91+1.96 (+1.34%) ▲|
30.2 C
New York
Friday, July 17, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Zilliz Transforms Video Surveillance Industry with AI-Powered Vector Database Solutions

Leading surveillance providers leverage Zilliz Cloud to overcome data overload challenges, enabling real-time threat detection and sub-second video search across enterprise installations. REDWOOD SHORES, Calif.,...

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Meta Develops Superintelligence Lab: Assessing AI’s Impact on Quantitative Models

**Title: Meta's Strategic Investment in AI: A Quantitative Perspective** **Introduction** Meta Platforms Inc. has announced a strategic $14.3 billion investment in a new artificial intelligence (AI)...

China, Central Asia make continuous efforts to deepen agricultural cooperation

BEIJING, June 15, 2025 /PRNewswire/ -- A report from People's Daily: ...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

SL Benfica President Rui Costa Inaugurates Portuguese club’s new Residential Academy in Florida

The "Eagles" have taken their world-famous player development methodology to the United States TAMPA, Fla., June 14, 2025 /PRNewswire/ -- SL Benfica President Rui Costa...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers